Compare Organon Pharma Indonesia Tbk. (SCPI) vs Dana Brata Luhur Tbk. (TEBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Dana Brata Luhur Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Dana Brata Luhur Tbk. trades at Rp1,715 (market cap 2.28T, 6.06M 24h volume). The key difference: Dana Brata Luhur Tbk. is far larger — about 21.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TEBE | |
|---|---|---|
Market Cap | 104.4B | 2.28T |
Volume | — | 6.06M |
Lot | — | 60.62K |
Turnover | — | 10.41B |
Average Price | — | 1,717.89 |
Value | — | 10.41B |
Indicative Equilibrium Price | — | 1,715 |
Indicative Equilibrium Volume | — | 1.6K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Dana Brata Luhur Tbk.
PT Dana Brata Luhur Tbk (the Company) was established based on Notarial Deed No. 52 dated June 26, 2008 of Bonar Sihombing, S.H., a public notary in Jakarta and the Deed of Amendment on the Articles of Association No. 2 dated December 18, 2008.
Read more on TEBE →
